Acuta Capital Partners buys $12.4 Million stake in Lion Biotechnologies Inc (LBIO)

Lion Biotechnologies Inc (LBIO) : Acuta Capital Partners scooped up 585,000 additional shares in Lion Biotechnologies Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 13, 2016. The investment management firm now holds a total of 2,500,000 shares of Lion Biotechnologies Inc which is valued at $12.4 Million.Lion Biotechnologies Inc makes up approximately 7.28% of Acuta Capital Partners’s portfolio.

Other Hedge Funds, Including , Nuveen Asset Management sold out all of its stake in LBIO during the most recent quarter. The investment firm sold 141,357 shares of LBIO which is valued $699,717.Teacher Retirement System Of Texas boosted its stake in LBIO in the latest quarter, The investment management firm added 1,355 additional shares and now holds a total of 5,274 shares of Lion Biotechnologies Inc which is valued at $26,106.Blackrock Investment Management boosted its stake in LBIO in the latest quarter, The investment management firm added 3,136 additional shares and now holds a total of 159,856 shares of Lion Biotechnologies Inc which is valued at $791,287.Blackrock Group Ltd boosted its stake in LBIO in the latest quarter, The investment management firm added 5,522 additional shares and now holds a total of 13,376 shares of Lion Biotechnologies Inc which is valued at $66,211.Proshare Advisors reduced its stake in LBIO by selling 4,365 shares or 9.7% in the most recent quarter. The Hedge Fund company now holds 40,657 shares of LBIO which is valued at $211,823.

Lion Biotechnologies Inc opened for trading at $5.74 and hit $5.97 on the upside on Wednesday, eventually ending the session at $5.93, with a gain of 3.49% or 0.2 points. The heightened volatility saw the trading volume jump to 1,07,514 shares. Company has a market cap of $288 M.

Lion Biotechnologies Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing adoptive cell therapy (ACT) using autologous tumor infiltrating lymphocytes (TILs) for the treatment of metastatic melanoma and other solid cancers. The Company’s program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL) which are T cells derived from patients’ tumors for the treatment of metastatic melanoma. Once the TILs have been multiplied to a sufficient number ex vivo and after the patient has completed the non-myeloablative chemotherapeutic regimen the TILs are infused into the patient along with a high dose of interleukin2 (IL2) a protein that stimulates the immune system.

Leave a Reply

Lion Biotechnologies Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Lion Biotechnologies Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.